French drugmaker Sanofi (Euronext: SAN) has unveiled positive results from the Phase III LUNA 3 trial of rilzabrutinib.
The trial met its primary endpoint of durable platelet response in people with persistent or chronic immune thrombocytopenia (ITP), a serious blood disorder.
People in the trial had been refractory to prior treatments, with a median of four prior ITP therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze